100,000 Shares in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Bought by Rhenman & Partners Asset Management AB

Rhenman & Partners Asset Management AB acquired a new position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 100,000 shares of the company’s stock, valued at approximately $2,501,000. Rhenman & Partners Asset Management AB owned 0.07% of Centessa Pharmaceuticals at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 26.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after acquiring an additional 979 shares during the period. TD Waterhouse Canada Inc. acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $25,000. Legal & General Group Plc grew its holdings in Centessa Pharmaceuticals by 3.5% during the third quarter. Legal & General Group Plc now owns 101,693 shares of the company’s stock worth $2,464,000 after acquiring an additional 3,437 shares during the period. DNB Asset Management AS grew its holdings in Centessa Pharmaceuticals by 41.8% during the fourth quarter. DNB Asset Management AS now owns 12,746 shares of the company’s stock worth $319,000 after acquiring an additional 3,758 shares during the period. Finally, Knott David M Jr acquired a new position in Centessa Pharmaceuticals during the fourth quarter worth $100,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Down 0.1%

CNTA opened at $39.72 on Friday. The business’s fifty day moving average is $39.64 and its two-hundred day moving average is $30.87. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The company has a market cap of $5.93 billion, a price-to-earnings ratio of -22.19 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $11.77 and a one year high of $40.26.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Insider Activity

In other news, insider Karen M. Anderson sold 41,076 shares of the company’s stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total value of $1,237,209.12. Following the sale, the insider directly owned 62,085 shares in the company, valued at $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold 115,887 shares of company stock valued at $3,346,523 in the last quarter. 4.09% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Needham & Company LLC downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. B. Riley Financial downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Stephens downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Wells Fargo & Company downgraded Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $35.00 to $42.00 in a research report on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $41.33.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.